KrammRL, NovackGD. Pipeline: US FDA efficacy requirements for treatment of ocular surface disease: Drugs vs. medical devices. Ocul Surf, 2025; 36:220–223.
2.
NovackGD. Pipeline: Patient, physician and developer view of drugs vs. devices. Ocul Surf, 2025; 38:260–261.
3.
KassMA, HeuerDK, HigginbothamEJ, et al.The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol, 2002; 120(6):701–713; discussion 829-830.
4.
KassMA, GordonMO, HoffMR, et al.Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. Arch Ophthalmol, 1989; 107(11):1590–1598.
5.
GroupGLTR. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol, 1995; 120:718–731.
6.
GargA, VickerstaffV, NathwaniN, et al.; Laser in Glaucoma and Ocular Hypertension Trial Study Group. Efficacy of repeat selective laser Trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT trial. Ophthalmology, 2020; 127(4):467–476.
7.
LichterPR, MuschDC, GillespieBW, et al.; CIGTS Study Group. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology, 2001; 108(11):1943–1953.
8.
WeinrebRN, KaufmanPL. Glaucoma research community and FDA look to the future, II: NEI/FDA glaucoma clinical trial design and endpoints symposium: Measures of structural change and visual function. Invest Ophthalmol Vis Sci, 2011; 52(11):7842–7851.
9.
WeinrebRN, LiebmannJM, CioffiGA, et al.Oral memantine for the treatment of glaucoma: Design and results of 2 randomized, placebo-controlled, phase 3 studies. Ophthalmology, 2018; 125(12):1874–1885.
